

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

28 January 2021 (28.01.2021)



(10) International Publication Number

WO 2021/014348 A1

(51) International Patent Classification:

A61K 9/14 (2006.01) A61K 31/573 (2006.01)

A61K 9/10 (2006.01) A61P 27/00 (2006.01)

A61K 47/02 (2006.01) C07J 31/00 (2006.01)

A61K 47/10 (2017.01) C07J 71/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/IB2020/056832

(22) International Filing Date:

21 July 2020 (21.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/877,599 23 July 2019 (23.07.2019) US

62/942,551 02 December 2019 (02.12.2019) US

(71) Applicant: NICOX OPHTHALMICS, INC. [US/US];
4721 Emperor Blvd. Suite 260, Durham, North Carolina
27703 (US).

(72) Inventors: BUKOWSKI, Jean-Michel; 347, Avenue Max
Camidas, Residence California Park Bat A, 06270 Vil-
leneuve Loubet (FR). NADKARNI, Akshay; 104, Disraeli
Drive, Cary, North Carolina 27513 (US). BOYER, José
L.; 103 Autumn Lane, Chapel Hill, North Carolina 27516
(US). DUQUESROIX-CHAKROUN, Brigitte; 3 Avenue
Saint Exupéry, 06800 Cagnes sur Mer (FR). NAVRATIL,
Tomas; 706 West Main Street, Carrboro, North Carolina
27510 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS FLUTICASONE PROPIONATE
FORM A NANOCRYSTALS SUSPENSIONS

(57) Abstract: The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.



WO 2021/014348 A1

**PROCESS FOR THE PREPARATION OF STERILE OPHTHALMIC AQUEOUS
FLUTICASONE PROPIONATE FORM A NANOCRYSTALS SUSPENSIONS**

Field of the Invention

The present invention relates to a process for the preparation of sterile topical ophthalmic nanosuspensions containing nanocrystals of fluticasone propionate Form A in an aqueous vehicle. This process is readily adaptable to preparation for large-scale
5 production and leads to sterile homogeneous aqueous nanosuspensions having a stable particle size distribution.

The sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals are useful in the treatment of eye inflammation diseases or eye inflammatory conditions through topical administration of said nanosuspensions (or
10 nanocrystals suspensions) to eyelids (e.g. upper and lower lids), eyelashes and eyelid margin.

Background of the Invention

Nanocrystals of fluticasone propionate Form A are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the
15 nanoplates. The fluticasone propionate Form A nanocrystals are prepared from a commercially available fluticasone propionate polymorph 1 by the anti-solvent sonocrystallization process disclosed in WO 2013/169647.

WO 2013/169647 discloses the preparation of nanocrystals of a morphic form of fluticasone propionate (Form A), their purification and also the preparation of the aqueous
20 suspensions containing said nanocrystals.

Briefly, according to the continuous sonicating flow-through scale-up process disclosed by WO 2013/169647 (Example 11 and Figure 38) the nanocrystals of fluticasone propionate are prepared using antisolvent crystallization under sonication followed by the thermal annealing of the nanosuspension; the generated nanocrystals are purified by
25 continuous flow centrifugation, the vehicle of the nanosuspension is centrifuged out, the

pellet is re-dispersed in the washing solution and the dispersion centrifuged again. This washing procedure is repeated several times to achieve the desired level of purification. The pellet is then dispersed into the final formulation composition to obtain the final product at required dose strength. However, WO 2013/169647 does not report any data
5 related to the sterility tests of the nanosuspension.

The applicant has found that the continuous sonicating flow-through process disclosed by WO 2013/169647 allows to prepare high amounts of fluticasone propionate Form A nanocrystals but it is not suitable for a large-scale preparation of sterile ophthalmic aqueous nanosuspensions because the dispersion of the purified nanocrystals (pellet) into
10 the final aqueous vehicle (see fig. 38) does not allow to produce a final product having the sterility requirements that must be met by pharmaceutical formulations for ocular delivery. Moreover, during the preparation of large-scale volumes of the nanosuspension it was found that, during the mixing of the purified nanocrystals with the final aqueous vehicle, the nanocrystals tended to form agglomerates that were difficult to be de-agglomerated
15 therefore making difficulty to obtain homogeneous nanosuspensions. Moreover, even when some effective deaggregation and homogenous nanosuspensions were obtained extemporaneously, these nanosuspensions exhibited some propensity to reaggregate and to be unstable.

As it is well known, nanoparticles have a high propensity to agglomerate due to
20 their high surface energy that cause the formation of agglomerates during the preparation and storage of the nanosuspensions,

Aggregation of the nanoparticles is not only a critical aspect during the manufacturing of the suspensions; agglomeration can cause a variety of issues, for example, inconsistent dosing and patient non-compliance. In particular, for nanosuspensions
25 intended for application onto the eyelids, eyelashes and eyelid margin, agglomeration, may impact the tolerability in patients and potential safety.

Several strategies to ensure proper physical stability of drug nanosuspensions are well known.

For example, stabilizers are usually used, however, the selection of an appropriate stabilizer for a certain drug can be challenging.

US 2018/0117064 discloses the preparation of aqueous suspensions containing nanoparticles of a glucocorticosteroid compound and a dispersion stabilizer. US
5 2018/0117064 discloses that the main function of the stabilizer is to wet the drug particles thoroughly to prevent Ostwald ripening and agglomeration of the nanosuspension and to form a physically stable formulation by providing steric or an ionic barrier. Typical examples of stabilizers used in nanosuspensions are celluloses, poloxamer, polysorbates, lecithin, polyoleate and povidones.

10 WO 2010/141834 discloses topical ophthalmic formulations of fluticasone propionate for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis. WO 2010/141834 discloses a variety of formulations including suspensions having a particle size no greater than 30 μm ; an example of vehicle comprises phosphate buffer, propylene glycol, hypromellose, polysorbate 80, edetate disodium and benzalkonium
15 chloride (page 14, lines, 7-15).

However, WO 2010/141834 does not report any method of preparation of the ophthalmic formulations and any experimental results related to the stability of the ophthalmic formulations.

WO 2013/025696 discloses the use of high pressure homogenization to prevent
20 formation of drug aggregates in an ophthalmic formulation containing an ophthalmic drug suspended in an aqueous vehicle containing at least one wetting agent. In particular the high pressure homogenization step may be used to prevent the formation of drug aggregates in the ophthalmic formulation when the drug particles are already present in a micronized form having particle sizes suitable for topical application; indeed WO 2013/025696
25 discloses that the high pressure homogenization may be applied to a suspension containing the pre-micronized drug in the aqueous solution of wetting agent and the high pressure homogenization does not bring about particle size reduction but instead stabilizes the already micronized drug, and thus prevent the formation of drug aggregates.

However, the process of WO 2013/025696 implies the use of high cost instruments that increases the cost of the dosage form, in addition, the use of high pressure homogenization could cause degradation of the nanocrystals.

The sonication process is commonly used for deagglomerating and dispersing
5 nanomaterials in aqueous based media, necessary to improve homogeneity and stability of the suspension. Despite its widespread use, sonication treatment tested during the setting up of the process for the preparation of the nanosuspensions of the present invention was not effective to deagglomerate fluticasone propionate nanocrystals.

Summary of the Invention

10 Therefore, there is a need to provide a large-scale process for the preparation of ophthalmic nanosuspensions (nanocrystals suspension) containing fluticasone propionate Form A nanocrystals in an aqueous vehicle.

As a result of studies performed to solve the above-mentioned problem, it was surprisingly found that mixing the nanocrystals of fluticasone propionate Form A with an
15 aqueous vehicle containing glycerin (glycerol) and boric acid under high-shear, high speed conditions stabilizes the nanocrystals. Without wishing to be bound by any theory, it is believed that glycerin and boric acid form a complex that behaves as stabilizer of the nanocrystals; the boric acid/glycerol complex prevents the formation of nanocrystals aggregates during the preparation of the nanosuspensions and also stabilizes the
20 nanosuspension during storage. The results of the studies also showed that adding the nanocrystals of fluticasone propionate Form A into the final vehicle containing the pre-formed boric acid/glycerol complex leads to a residual aggregation which is not observed when the nanosuspension is prepared according to the process of the present invention wherein glycerol is added after the nanocrystals of Fluticasone propionate are
25 suspended and de-agglomerated in a vehicle that contains boric acid but no glycerol. When the nanocrystals of Fluticasone propionate are directly suspended and de-agglomerated in a final vehicle that contains the pre-formed boric acid/glycerol complex the stabilizing effect is lost and the de-agglomeration of the nanocrystals is more difficult to achieve and

to maintain during the storage.

Complexes of boric acid with polyhydroxyl compounds (borate-polyol complexes) are well known and it is generally known the use of borate-polyol complexes in ophthalmic composition to enhance antimicrobial activity.

5 WO 93/21903 discloses borate-polyol complexes, such as mannitol, glycerol and propylene glycol, as adjunctive disinfecting agent in contact lens disinfecting solutions.

WO 2010/148190 discloses borate-polyol complexes including two different polyols to improve preservation of multi-dose ophthalmic compositions.

The present invention relates to a process for the preparation of sterile topical
10 ophthalmic aqueous suspensions containing fluticasone propionate Form A nanocrystals that is readily adaptable to large-scale preparation for commercial production and gives rise to stable nanosuspensions with a homogenous reproducible particle size distribution.

For this invention “fluticasone propionate Form A nanocrystals” refer to fluticasone propionate Form A nanocrystals that have mean particle size from 100 nm to 1000 nm, a
15 X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2θ , and wherein the said nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

20 **Description of Figures**

Figure 1: the XRPD pattern of fluticasone propionate Form A nanocrystals

Figure 2: Particle size distribution graph at T = 1 week at 40°C; 0.25% fluticasone propionate Form A nanocrystals in a vehicle containing a pre-formed 1% w/w boric acid / 0.25% w/w glycerol complex (comparative example).

25 Figure 3: Particle size distribution graph at T = 1 week at 40°C; 0.25% fluticasone propionate Form A nanocrystals in a vehicle containing a pre-formed 1% w/w boric acid 1% w/w glycerol (comparative example).

Figure 4: Particle size distribution graph at T = 1 week at 40°C, refrigerated for 20

hours storage at 5°C after initial analysis at 40°C; 0.25% w/w fluticasone propionate Form A nanocrystals in a vehicle with 0.25% w/w glycerol (comparative example).

Description of the invention

The present invention relates to a process for the preparation of sterile topical
5 ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A
nanocrystals having a mean particle size from 100 nm to 1000 nm and a concentration of
fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:

- 10 a) preparing an aqueous vehicle 1 containing: 0.5 % w/w methylcellulose 4000
cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w
sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80,
hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5
and water to 100% w/w;
- 15 b) mixing an amount of fluticasone propionate nanocrystals form A having a mean
particle size from 100 nm to 1000 nm with an amount of aqueous vehicle 1 to obtain
a slurry containing a concentration of fluticasone propionate of 2% w/w;
- c) applying high-shear high-speed mixing to the slurry of step b) for at least 10
minutes;
- 20 d) preparing an aqueous vehicle 2 containing: 1.8% w/w glycerin, 0.5 % w/w
methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium
dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2%
w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust
the pH at 7.3 – 7.5 and water q.s. to 100% w/w;
- e) adding an aliquot of the aqueous vehicle 2 to the slurry of step c) to obtain a
concentration of fluticasone propionate of about 1% w/w;
- 25 f) applying high-shear, high-speed mixing to the slurry of step e) till to obtain the
targeted mean particle size;
- g) sterilizing the nanosuspension of step f) by autoclaving;
- h) preparing an aqueous vehicle 3 containing: 0.9% w/w glycerin, 0.5 % w/w

methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w; and sterilizing the aqueous vehicle
5 3 by filtration;

i) aseptically adding an aliquot of the sterile aqueous vehicle 3 to the sterilized nanosuspension of step g) to prepare a sterile topical ophthalmic aqueous nanosuspensions containing the targeted concentration of fluticasone propionate nanocrystals Form A;

10 wherein the nanocrystals of fluticasone propionate Form A have an X-ray powder diffraction pattern of said nanocrystals includes peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the
15 nanoplates.

In step c) the high-shear, high speed mixing of the slurry containing the nanocrystals of fluticasone propionate form A and the aqueous vehicle 1, which does not contain glycerin, is conducted to ensure an even distribution of the fluticasone propionate nanocrystals to improve the homogeneity of the final nanosuspension.

20 Preferably in step c) and in step f) the high-shear, high-speed mixing is performed at 6000 RPM.

Preferably the high-shear, high-speed mixing of step f) is applied for at least 10 minutes.

25 Preferably the sterilization of step g) of the nanosuspension of step f) containing a concentration of fluticasone propionate of 1% w/w is performed by autoclaving the nanosuspension in glass bottles at about 122 °C for about 40 minutes.

Preferably the aqueous vehicles 1 and 2 are filtered through 0.2 μm filter before their use in step b) and step e) respectively.

Optionally the aqueous vehicle 2 containing glycerin 1.8% w/w may be prepared by adding to an aliquot of vehicle 1 filtered through 0.2 μm filter an amount of glycerin to obtain a final concentration of glycerin of 1.8% w/w.

Preferably in the final sterile topical ophthalmic aqueous nanosuspensions prepared according to the process of the invention the concentration of fluticasone propionate is from 0.001% to 0.5% w/w; more preferably the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; most preferably the concentration of fluticasone propionate is 0.20% w/w or 0.10% w/w or 0.05% w/w.

Alternatively, the process of the present invention may be performed under fully aseptic manufacturing conditions utilizing sterilized Fluticasone propionate Form A nanocrystals and sterilized vehicles 1 to 3, accordingly another embodiment of the present invention relates to a process for the preparation of sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm and a concentration of fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:

- a-1) sterilizing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm;
- b-1) preparing an aqueous vehicle 1 containing: 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w; and sterilizing said aqueous vehicle 1 by filtration;
- c-1) aseptically mixing an amount of sterilized fluticasone propionate nanocrystals form A with an amount of the sterilized aqueous vehicle 1 to obtain a slurry containing a concentration of fluticasone propionate of 2% w/w;
- d-1) applying high-shear, high-speed mixing to the slurry of step c-1) for at least 10 minutes;

e-1) preparing an aqueous vehicle 2 containing: 1.8% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w; and sterilizing said aqueous vehicle 2 by filtration;

f-1) aseptically adding an aliquot of the sterilized aqueous vehicle 2 to the slurry of step d-1) to obtain a concentration of fluticasone propionate of about 1% w/w;

g-1) applying high-shear, high-speed mixing to the slurry of step f-1) till to obtain the targeted mean particle size;

h-1) preparing an aqueous vehicle 3 containing: 0.9% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N / sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water to 100% w/w; and sterilizing said aqueous vehicle 3 by filtration;

i-1) aseptically adding an aliquot of the sterilized aqueous vehicle 3 to the nanosuspension of step g-1) to prepare a sterile topical ophthalmic aqueous nanosuspensions containing the final concentration of fluticasone propionate nanocrystals Form A;

wherein the nanocrystals of fluticasone propionate Form A have a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

Preferably the fluticasone propionate Form A nanocrystals used in step a-1) are sterilized by autoclaving a suspension of fluticasone propionate Form A nanocrystals in water for injection having a concentration of fluticasone propionate between 2 % to 20 %

w/w; preferably the suspension of fluticasone propionate Form A nanocrystals in water is autoclaved at about 122 °C for about 30 minutes.

Preferably in step d-1) and step g-1) the high-shear, high-speed mixing is performed at 6000 RPM.

5 Preferably the high-shear, high-speed mixing of step g-1) is applied for at least 10 minutes.

Preferably in the sterile topical ophthalmic aqueous nanosuspensions prepared according to the process of the invention the concentration of fluticasone propionate is from 0.001% to 0.5% w/w; more preferably the concentration of fluticasone propionate is 0.5%
10 w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; most preferably 0.20% w/w or 0.10% w/w or 0.05% w/w.

Preferably fluticasone propionate Form A nanocrystals used in the process of the present invention are prepared according to a general method reported below that comprises the following steps:

15 1) preparing a phase I solution comprising: 0.45% w/w fluticasone propionate polymorph 1, 23,2% w/w polyethylene glycol 400 (PEG 400), 68.8% w/w polypropylene glycol 400 (PPG 400), and 7.6% w/w polysorbate 80 (Tween 80); and filtering the phase I solution through 0.8/0.2 µm Polyethersulfone (PES) filter;

20 2) preparing a phase II solution comprising: 0.01% w/w benzalkonium chloride, 0.40% w/w methyl cellulose 15 cP, 0.1% w/w polyethylene glycol 40 stearate (PEG-40 stearate), citrate buffer to pH 3.4 to 3.8 and water q.s. to 100% w/w, and filtering the phase II solution through 0.8/0.2 µm Polyethersulfone (PES) filter;

3) cooling the filtered phase I and phase II solutions to a temperature from 0 to 4°C;

25 4) mixing the phase I and the phase II solutions in a reactor equipped with ultrasonic transducer (for example QSonica Q2000 Ultrasonic transducer) to obtain a phase III suspension of nanocrystals, wherein:

- the phase I solution and the phase II solution are pumped continuously into the

reactor at flow rates of 600 ml/min (phase I solution) and 2400 ml/min (phase II solution) respectively to obtain a phase III suspension;

- the volumes ratio phase I and phase II is 1:4;

- the sonication is applied during the mixing with an output power of 60%;

5 - the average temperature of phase III suspension is about 11 °C;

5) low shear mixing phase III suspension of step 4) at sufficient speed to create a vortex, at room temperature for a minimum of 30 minutes in absence of sonication;

6) annealing the phase III suspension at 40°C over a period of time not less than 16 hours;

10 7) preparing a buffer solution comprising: 0.2% w/w polyethylene glycol 40 stearate (PEG-40 stearate), 0.2% w/w polysorbate 80 (Tween 80), 0.001% w/w benzalkonium chloride, 0.05% w/w sodium phosphate monobasic monohydrate, 0.02% w/w sodium phosphate dibasic dihydrate and water q.s. to 100% w/w, having a pH 6.3 ± 0.2 ; and filtering the buffer solution through 0.8/0.2 μm Polyethersulfone (PES) filter;

15 8) diluting the phase III suspension of step 6) with the filtered buffer solution wherein the volumes ratio buffer solution and phase III is 1:1;

9) centrifuging the diluted phase III suspension to recover the fluticasone propionate nanocrystals Form A and washing the recovered nanocrystals;

10) washing the collected nanocrystals with water for injection.

20 When the process of the invention is performed under fully aseptic manufacturing conditions the washed nanocrystal of step 10) are sterilized before their use for the preparation of the sterile topical ophthalmic aqueous nanosuspensions; for example, the washed nanocrystals are suspended in water for injection at a fluticasone propionate concentration between 2 % to 20 % w/w, and autoclaved at about 122 °C for 30 minutes.

25 Another embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and consisting of:

(a) 0.001% to 1% w/w fluticasone propionate Form A nanocrystals;

(b) 0.50% w/w methylcellulose 4000 cp;

(c) 0.2% w/w polysorbate 80;

(d) 0.10% w/w edetate disodium dihydrate;

(e) 1.0 % w/w boric acid;

5 (f) 0.9% w/w glycerin;

(g) 0.01% w/w benzalkonium chloride;

(h) 0.055% w/w sodium chloride;

(i) hydrochloric acid (1N) and/or sodium hydroxide (1N) as adjusting agents in an amount sufficient pH from 7.3-7.5; and

10 (j) water q.s. to 100% w/w,

wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are
15 nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

Preferably, in the topical ophthalmic aqueous nanosuspension the concentration of fluticasone propionate is from 0.001% to 0.5% w/w, more preferably the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.1% w/w, 0.05% w/w, 0.03%
20 w/w, 0.01% w/w or 0.005% w/w. Most preferably in the topical ophthalmic aqueous nanosuspension the concentration of fluticasone propionate is 0.1% w/w, 0.20% w/w or 0.05% w/w.

Another embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and
25 consisting of:

(a) 0.1% w/w, or 0.5% w/w, or 0.25% w/w, or 0.20% w/w or 0.05% w/w fluticasone propionate Form A nanocrystals;

(b) 0.50% w/w methylcellulose 4000 cp;

(c) 0.2% w/w polysorbate 80;

(d) 0.10% w/w edetate disodium dihydrate;

(e) 1.0 % w/w boric acid;

(f) 0.9% w/w glycerin;

5 (g) 0.01% w/w benzalkonium chloride;

(h) 0.055% w/w sodium chloride;

(i) hydrochloric acid (1N) and/or sodium hydroxide (1N) as adjusting agents in an amount sufficient pH from 7.3-7.5; and

(j) water q.s. to 100% w/w,

10 wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that
15 define the thickness of the nanoplates.

Another preferred embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and consisting of:

(a) 0.1% w/w, or 0.20% w/w or 0.05% w/w fluticasone propionate Form A
20 nanocrystals;

(b) 0.50% w/w methylcellulose 4000 cp;

(c) 0.2% w/w polysorbate 80;

(d) 0.10% w/w edetate disodium dihydrate;

(e) 1.0 % w/w boric acid;

25 (f) 0.9% w/w glycerin;

(g) 0.01% w/w benzalkonium chloride;

(h) 0.055% w/w sodium chloride;

(i) hydrochloric acid (1N) and/or sodium hydroxide (1N) as adjusting agents in an

amount sufficient pH from 7.3-7.5; and

(j) water q.s. to 100% w/w,

wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at
5 about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

The sterile topical ophthalmic aqueous nanosuspensions prepared according to the
10 process of the present invention have some advantages, for example better tolerability upon administration onto eyelids (e.g. the upper and lower eyelids), eyelashes or eyelid margin due to the small particles sizes and maintenance of drug release over a prolonged period of time that allows reducing the amount of the active principle to be administered and, consequently, reducing the systemic exposure to fluticasone propionate as well as reducing
15 the exposure to other structure of the eye. As it is well known, corticosteroids have side effects such as the increase of the intra-ocular pressure (IOP), the increase of corneal thickness, mydriasis, ptosis, cataract, glaucoma, adrenal suppression, decrease in bone mineral density; therefore low systemic exposure an overall eye are an important advantages of the ophthalmic aqueous nanosuspensions prepared according to the process
20 of the present invention in particular for therapeutic applications that require long-term or repetitive corticosteroid treatment.

The sterile topical ophthalmic aqueous nanosuspension of the present invention has high efficacy and local tolerability without the unwanted side-effects associated with the systemic absorption of the fluticasone propionate active ingredient.

25 In another embodiment, the nanosuspension of the present invention may be used in a method for treating or reducing the symptoms and/or clinical signs associated with eye inflammation diseases or eye inflammatory conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease by topical administration of

said composition to the eye lids, eye lashes or eye lid margin of a subject in need.

Such method for treating blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease comprises the step of topically administering to a subject's eyelids, eyelashes or eyelid margin an effective amount of the nanosuspension of the present
5 invention.

Another embodiment of the invention provides a method of treatment and or reducing the symptoms and/or clinical signs associated with blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease, the method comprising administering an effective amount of a pharmaceutical composition to a subject in need
10 thereof wherein the pharmaceutical composition is an ophthalmic aqueous nanosuspension consisting of: 0.001% to 1% w/w nanocrystals of fluticasone propionate Form A, 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid, 0.9% w/w glycerin, 0.01% w/w benzalkonium chloride, 0.055% w/w sodium chloride, hydrochloric acid 1N and / or sodium hydroxide 1N as
15 adjusting agents in an amount sufficient pH from 7.3-7.5, and water q.s. to 100% w/w, wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having
20 the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates, wherein the ophthalmic aqueous nanosuspension is administered topically to the upper and/or lower eye lid margins, Meibomian gland ducts eyelashes or any area of the eye lid anatomy. Preferably the ophthalmic aqueous nanosuspension used in the method of the invention contain a concentration of fluticasone propionate Form A
25 nanocrystals of 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; more preferably the concentration of fluticasone propionate Form A nanocrystals in the ophthalmic aqueous nanosuspension is of 0.1% w/w, 0.20% w/w 0.25% w/w, 0.5% w/w, 0.05% w/w or 0.01% w/w; most preferably the concentration

of fluticasone propionate Form A nanocrystals is 0.1% w/w, 0.20% w/w or 0.05% w/w.

Typical clinical signs associated with blepharitis and Meibomian gland dysfunction include lid debris, redness of eyelid margin, eyelid swelling, obstruction of the Meibomian gland, and or qualitative/quantitative changes in Meibomian gland secretion.

5 The most common symptoms associated with dry eye, which is also known as keratoconjunctivitis sicca, include eye dryness, eye discomfort, eye redness, a stinging, burning or scratchy sensation in the eyes, watery eyes, sensitivity to light, blurred vision, pain or eye fatigue.

The method of the invention is preferably directed to a method for treating non-
10 infectious, inflammatory blepharitis or Meibomian gland dysfunction in a subject.

In another embodiment, a subject is administered with topical ophthalmic aqueous nanosuspension of the present invention at least once a day, preferably subject is administered with the pharmaceutical formulation once a day.

In another embodiment, a subject is administered with topical ophthalmic aqueous
15 nanosuspension of the present invention at least once a day for at least two weeks, more than two weeks, at least three weeks, or at least four weeks.

Another embodiment of the present invention relates to a kit comprising (a) the above reported topical administrable ophthalmic aqueous nanosuspension containing fluticasone propionate Form A nanocrystals and (b) a swab or sponge to apply the
20 nanosuspension to the eyelids, eyelashes or eyelid margin.

Examples

The percentage (%) as used herein in the compositions and in the examples refers to weight percentage (w/w) unless otherwise stated. The terms glycerin and glycerol in the text and in the examples are used as synonyms.

25 Example 1

Preparation of nanocrystals of fluticasone propionate form A

Preparation of Phase I solution

In a 2 L process vessel, 106.26 g polysorbate 80 (Tween 80), 963.34 g

polypropylene glycol 400 (PPG 400), 324.10 g polyethylene glycol 400 (PEG 400), were added at room temperature and stirred together until all components were dissolved, then 6.3 g fluticasone propionate polymorph 1 was added into the solution and stirred until a clear solution was obtained. The obtained solution was filtered using a 0.8/0.2 μm Polyethersulfone (PES) filter and kept refrigerated at 2-8 °C until use.

Preparation of Phase II solution

In an 8 L process vessel an initial quantity of about 5276 g of purified water was added and stirred with an over-head mixer so that a vortex was generated.

6.01 g polyethylene glycol 40 stearate (PEG-40 stearate), 5.98 g benzalkonium chloride (solution 10%), and 24.02 g methyl cellulose 15 cP were added and stirred till methyl cellulose was completely dissolved. Citrate buffer was added to adjust the pH to 3.5 – 4.0 and 585.8 g water were added. The final pH of the phase II solution was 3.83

Phase II was then filtered using a 0.8/0.2 μm Polyethersulfone (PES) filter and kept refrigerated at 2-8°C until use.

Preparation of dilution buffer solution

In a 20 L process vessel, 12.0 g polysorbate 80 (Tween 80) were introduced, 5374 g purified water were added, and stirred with an over-head mixer so that a vortex was generated.

3.24 g sodium phosphate monobasic monohydrate, 1.14 g sodium phosphate dibasic dihydrate, 12.00 g polyethylene glycol 40 stearate (PEG-40 stearate), 0.6 g benzalkonium chloride (solution 10%) were added and stirred until complete dissolution, and 597 g water were added. The final pH of the buffer solution was 6.4. This solution was filtered using a 0.8/0.2 μm Polyethersulfone (PES) filter and kept refrigerated at 2-8 °C until use.

Preparation of nanocrystal of fluticasone propionate form A

480g of phase II were introduced into the chamber of the reactor. 940 g phase I and 3780 g phase II were allowed to cool down to a target temperature of 2-4 °C in their jacketed vessels connected to chillers.

Using peristaltic calibrated pumps phase I and phase II were pumped (pump flow

rates for phase I and phase II were respectively 600 ml/min and 2400 ml/min) through the reactor fitted with its ultrasonic transducer with an amplitude set at 60% (Q Sonica Q1375 W).

The outflow from the reactor (phase III: 5201.7 g) was collected into a clean vessel at room temperature. The temperature of phase III was about 11°C.

Then phase III was stirred at room temperature for about 30 minutes in the collecting vessel to obtain a uniform suspension of fluticasone propionate nanocrystals (final phase III).

Annealing process

The final phase III was transferred into a closed container. The container was placed in an incubator and maintained at 40°C for at least 16 hours.

Purification and isolation of nanocrystals

5167 g of the annealed phase III were transferred into a process vessel and an equivalent amount of dilution buffer solution was added, so that the ratio of phase III to dilution buffer solution was 1:1. The resulting mixture was stirred with a low shear mixer for 30 minutes to achieve a homogeneous suspension of nanocrystals (diluted phase III).

The diluted phase III was kept refrigerated at 2-8°C until centrifugation.

The fluticasone propionate Form A nanocrystals were first collected by discontinuous centrifugation of the diluted phase III. The nanocrystals were then washed several times (4 washing cycles) with water for injection.

The particle size of the isolated nanocrystals was evaluated using a laser scattering Particle size distribution analyzer (Horiba LA-950). The D₅₀ was 0.2153 μm and the D₉₀ was 0.6073 μm

Characterization of the nanocrystals was performed by XRPD and Rietveld refinement. Results are provided in Figure 1 (XRPD) showing the typical pattern of Fluticasone propionate form A, having a crystal habit with strong preferred orientation and c-axis substantially normal to the surface, as defined in WO 2013/169647 confirmed by pole figure obtained from Rietveld refinement.

Example 2**Preparation of a sterile topical ophthalmic aqueous nanosuspension of fluticasone propionate Form A**

Table 1	
Fluticasone propionate nanosuspension composition	
Ingredients	Amount (% w/w)
Fluticasone propionate Form A nanocrystals	0.10
Methylcellulose 4000 cP	0.50
Polysorbate 80	0.2
Edetate disodium, dihydrate	0.10
Boric acid	1.0
Glycerin	0.9
Benzalkonium chloride	0.01
Sodium chloride	0.055
Water for injection	q.s. to 100 %
pH	7.3 – 7.5

5 Step 1) Preparation of vehicle 1 (vehicle without glycerin)

In a 20 L process vessel, 17600 g water for injection were heated at 80°C, 100.0 g methylcellulose 4000 cp were slowly added and the mixture is stirred until methylcellulose was dissolved.

The solution was cooled at 40°C, 200.0 g boric acid was added and the pH was
10 adjusted at 7.4 with sodium hydroxide (1N).

The following excipients were added in the specific following order: 20.0 g edetate disodium dihydrate, 11.0 g sodium chloride, 4.0 g benzalkonium chloride (solution 50%), 40.0 g polysorbate 80 (Tween 80); each excipient being fully dissolved before adding the next excipient and the preparation of the solution is carried out at a temperature of about
15 40°C to room temperature. The pH was tested and optionally adjusted at 7.3 – 7.5 with hydrochloric acid (1N) or sodium hydroxide (1N); after the pH adjustment, water for injection was added to bring the final weight to 19800 g. The resulting solution was mixed for at least 10 minutes to obtain a uniform solution which was stored at 2-8°C.

Step 2) Preparation of the 2% fluticasone propionate nanocrystals slurry

20 4000 g of vehicle 1 were introduced into a 10 L process vessel containing a stir bar,

by filtration through a PES 0.2 μm media and were set aside for further use.

In a 2 L beaker, 15.04 g of the fluticasone propionate Form A nanocrystals were introduced together with some vehicle 1. This slurry was mixed for homogeneity and assayed for fluticasone propionate content (31.6 mg/g), then it was further diluted with vehicle 1 so as to achieve a target concentration of fluticasone propionate of 20 mg/ml (2% w/w slurry). This concentrated slurry was subject to high-shear, high-speed mixing at 6000 ± 10 RPM for 10 minutes and the particle size distribution was tested by laser diffraction on a Horiba LA-950S2 PSD analyzer.

The results were the following:

10

Mean:	0.856 μm
Mode:	0.363 μm
Median:	0.420 μm
D ₁₀ :	0.203 μm
D ₉₀ :	2.154 μm

Step 3) Preparation of vehicle 2 (vehicle containing glycerin 1.8% w/w)

In a 4 L beaker, 1600 g of the filtered vehicle 1 were introduced, and 36 g glycerin were added under stirring until dissolution.

The pH was tested and adjusted at 7.3 – 7.5 with sodium hydroxide (1N) and vehicle 1 was further added to adjust the final weight to 2000g, leading to a 1.8% w/w glycerin solution.

Step 4) Preparation of the 1% fluticasone propionate nanocrystals slurry

The 1% fluticasone propionate nanocrystals slurry was prepared by further diluting the 2% concentrated slurry prepared in Step 2) with vehicle 2 down to a concentration of fluticasone propionate of 1% w/w.

The 1% w/w fluticasone propionate Form A nanocrystals slurry was subject to high-shear, high-speed mixing at 6000 ± 10 RPM for 10 minutes and the particle size distribution was tested by laser diffraction using a Horiba LA-950S2 PSD analyzer.

The results were the following:

25

21

Mean: 0.428 μm
Mode: 0.123 μm
Median: 0.162 μm
D₁₀: 0.082 μm
D₉₀: 0.678 μm

Aliquots of the 1% concentrated slurry were filled into 500 ml glass bottles containing stir bar and sterilized by autoclaving at 121.5 °C for 40 minutes.

Step 5) Preparation of vehicle 3 (vehicle containing glycerin 0.9% w/w)

In a 20 L container, 11200 g of vehicle 1 were introduced, 126 g of glycerin were added under stirring and the pH was then adjusted with sodium hydroxide to 7.3-7.5 and an aliquot of vehicle 1 was further added to adjust the final weight to 14000 g, leading to a 0.9% w/w glycerol solution. This solution was mixed for at least 10 minutes until uniform and sterile filtered into another receiving vessel.

Step 6) Preparation of the 0.1% w/w fluticasone propionate nanosuspension.

In an ISO 5 environment, the content of the bottles containing the autoclaved sterile 1% w/w fluticasone propionate nanocrystals of Step 4) were aseptically transferred and pooled into a final compounding vessel.

The weight of the 1% fluticasone propionate nanocrystals slurry transferred in the vessel was recorded (1366.3g).

The final 0.1% sterile fluticasone propionate nanocrystal suspension was obtained by adding 11774.2g of the sterile vehicle 3.

The final sterile nanosuspension was stirred for not less than 15 minutes on a stir plate.

The particle size distribution was tested by laser diffraction using a Horiba LA-950S2 PSD analyzer.

The results were the following:

Mean: 0.846 μm
Mode: 0.362 μm
Median: 0.425 μm
D₁₀: 0.202 μm
D₉₀: 2.219 μm

Nanosuspensions according to the invention containing different concentrations of fluticasone propionate form A such as 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.1% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w and 0.005% w/w were obtained by diluting the de-agglomerated 1% fluticasone propionate nanosuspension of step 4) with aliquots of aqueous vehicle 3 as disclosed in step 6) to obtain the final fluticasone propionate concentration.

Example 3

Evaluation of the stability of the nanosuspension of Example 2

The nanosuspension composition prepared in example 2 was subjected to storage stability testing by storing the nanosuspension at three different temperatures and humidity conditions (5°C, 25°C / 40% RH; 40°C / 25% RH) The resuspendability of the nanosuspension, the content of fluticasone propionate, the particle size distribution and the content of benzalkonium chloride were assessed at 1 month and 3-month time-points.

The results reported in tables 2 and 3 show that the nanosuspension was physically and chemically stable upon manufacture and storage. No change in physical appearance of the nanosuspension upon storage was noticed. The nanosuspension did not show any sign of chemical degradation as the chemical assay of fluticasone propionate was well within the limit of 90% - 110% of the label claim upon storage. The related substances and total impurities remained within the specified limits of not more than 4%, upon storage.

Parameter	T0	T = 1 month		
		5°C	25°C 40% RH	40°C 25% RH
Fluticasone propionate assay	105.6%	103.8 %	98.2 %	101.2%
Fluticasone Propionate Related substances (total)	0.0%	0.25%	0.10%	0.11%
Resuspendability	n/a	Readily resuspends	Readily resuspends	Readily resuspends
BAK content	99.1%	98%	97%	98%
PSD results (µm)				
Mean	0.846	0.816	0.796	0.825

Table 2: 1-month time-point stability data				
Parameter	T0	T = 1 month		
	n/a	5°C	25°C 40% RH	40°C 25% RH
Median	0.425	0.461	0.412	0.455
Mode	0.362	0.366	0.363	0.366
D ₁₀	0.202	0.213	0.200	0.212
D ₉₀	2.219	1.731	1.991	1.866

Table 3: 3-month time-point stability data				
Parameter	T0	T = 3 months		
	n/a	5°C	25°C 40% RH	40°C 25% RH
Fluticasone propionate assay	105.6%	103%	104%	104%
FP Related substances (total)	0.0%	0.11%	0.12%	0.11%
Resuspendability	n/a	Resuspends	Resuspends	Resuspends
BAK content	99.1%	101%	101%	97%
PSD results (µm)				
Mean	0.846	0.830	0.830	0.770
Median	0.425	0.460	0.480	0.330
Mode	0.362	0.370	0.420	0.320
D ₁₀	0.202	0.220	0.230	0.170
D ₉₀	2.219	1.980	1.890	2.250

Example 4 (Comparative example)

The results of this study show that nanosuspensions of fluticasone propionate Form A nanocrystals containing boric acid but no glycerin are not stable and aggregate.

- 5 Fluticasone propionate Form A nanocrystals were suspended in a vehicle containing the exact same concentrations of boric acid and of methylcellulose as in the previous Example 2 but it does not contain glycerol.

The compositions of the tested nanosuspensions are reported in Table 4.

Table 4: Tested nanosuspensions					
Ingredient	Concentration (% w/w)				
Fluticasone Propionate	0.1	0.03	0.01	0.005	N/A
Methylcellulose 4000cP	0.5	0.5	0.5	0.5	0.5
Polysorbate 80 (Tween 80)	0.2	0.2	0.2	0.2	0.2
Edetate disodium, dihydrate	0.1	0.1	0.1	0.1	0.1
Boric acid	1.0	1.0	1.0	1.0	1.0
Sodium chloride	0.055	0.055	0.055	0.055	0.055
Glycerin	0	0	0	0	0
Benzalkonium chloride	0.01	0.01	0.01	0.01	0.01
Water for Injection	q.s. to 100	q.s. to 100	q.s. to 100	q.s. to 100	q.s. to 100

Preparation of the fluticasone propionate Form A nanocrystal suspensions

An amount of Fluticasone propionate Form A nanocrystals were suspended in aliquots of vehicle consisting of: 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid; 0.01% w/w benzalkonium chloride and water q.s to 100% w/w (see Table 4), to get the targeted concentrations of fluticasone propionate (see Table 4). Once the nanocrystals were suspended, the suspension was poured into a 500mL glass beaker for deagglomeration using a high-speed, high-shear Silverson mixing apparatus. The suspension was mixed at 6000 RPM until particle size distribution specifications were met. The particle size distribution and the viscosity of the nanosuspensions were measured.

The nanosuspensions were placed on stability at 40°C, the particle size distribution (PDS) and the viscosity were measured at 2-week time point.

The results reported in Tables 5a and 5b show that over a short period of two weeks only, there was an increase of the mean particle size and of the D₉₀, reflecting the formation of aggregates in the nanosuspensions; conversely the stability results reported in Example 3 show that the nanosuspension prepared according to the process of the invention was stable under accelerated conditions up to 3 months.

Table 5a		
PSD and viscosity assessments		
Time	T0	2 weeks
Formulation containing 0.1% of Fluticasone propionate		
Viscosity in cP	18.6	15.7
Particle Size Distribution results in μm		
Mode	0.212	0.183
Median	0.245	0.261
Mean	0.382	2.575
D ₁₀	0.137	0.261
D ₉₀	0.754	7.571
Formulation containing 0.03% of Fluticasone propionate		
Viscosity in cP	19.7	15.6
Particle Size Distribution results in μm		
Mode	0.317	0.210
Median	0.319	0.291
Mean	0.437	2.128
D ₁₀	0.161	0.141
D ₉₀	0.829	6.279

Table 5b		
PSD and viscosity assessments		
Time	T0	2 weeks
Formulation containing 0.01% of Fluticasone propionate		
Viscosity in cP	19.7	15.1
Particle Size Distribution results in μm		
Mode	0.319	0.317
Median	0.336	0.467
Mean	0.463	1.808
D ₁₀	0.179	0.197
D ₉₀	0.854	4.719
Formulation containing 0.005% of Fluticasone propionate		
Viscosity in cP	19.3	16.3
Particle Size Distribution results in μm		
Mode	0.319	0.318
Median	0.337	0.427
Mean	0.382	1.050
D ₁₀	0.179	0.190
D ₉₀	0.931	2.619
Formulation containing 0.0% of Fluticasone propionate		
Viscosity in cP	18.6	16.6

Example 5 (Comparative example)

The results of this study confirmed that adding the Fluticasone propionate Form A nanocrystals into a vehicle containing the pre-formed boric acid / glycerol complex leads

to a residual aggregation which is not observed when the nanosuspension is prepared according to the process of the present invention wherein the glycerol is added to the high speed high, shear mixing de-agglomerated 2% fluticasone propionate nanocrystals slurry (see Example 2 – Step 4).

5 Fluticasone propionate Form A nanocrystals were suspended and de-agglomerated in the vehicle containing the pre-formed boric acid/glycerol complex (boric acid 1.0% w/w /glycerol 0.25% w/w and boric acid 1.0% w/w /glycerol 1.0% w/w) to get a final concentration of Fluticasone propionate of 0.25% w/w.

The compositions of the vehicles of the two tested nanosuspensions are reported in

10 Table 6.

Table 6: Tested nanosuspensions		
Ingredient	Concentration (% w/w)	
Fluticasone Propionate	0.25	0.25
Methylcellulose 4000cP	0.5	0.5
Tween 80	0.2	0.2
EDTA disodium, dihydrate	0.1	0.1
Boric acid	1.0	1.0
Sodium chloride	0.05	0.05
Glycerol	0.25	1.0
Benzalkonium chloride	0.01	0.01
Water for Injection	q.s. to 100	q.s. to 100

Preparation of the fluticasone propionate Form A nanocrystal nanosuspensions

15 Fluticasone propionate Form A nanocrystals were suspended in the two vehicles reported in Table 6 that contain the pre-formed boric acid / glycerol complex and stirred overnight on a magnetic stir plate, using a stir bar. Once the nanocrystals were suspended, the suspension was poured into a 500mL glass beaker for de-agglomeration using a high-speed, high-shear, Silverson mixing apparatus. The suspension was mixed at 6000 RPM until particle size distribution specifications were met.

20 The two formulations were placed on stability at 40°C and the particles size distribution was measured on samples pulled out at 1-week time point. The samples were analyzed shortly after being pulled from the stability chamber. The results show a great

deal of aggregation in the samples (see Figures 2 and 3).

The aggregation was partly reversible when the samples were refrigerated but there still was a substantial residual level of aggregation (see Figure 4); this thermo-reversible aggregation was related to the decrease of the solubility of the methylcellulose when the temperature increases. It is known that even though methylcellulose solutions are visually clear with no detectable particles in the range of 30-50 °C, the polymer chains form loosely-associated clusters that grow in size as the temperature increases. These clusters are likely responsible for part of the aggregation of the nanocrystals at 40°C.

As reported above, the results of this study demonstrated that glycerol acts as a stabilizer by forming a complex with the boric acid that prevents the aggregation of the isolated nanocrystals. If the nanosuspension is prepared by suspending the nanocrystals in the vehicle that contains the pre-formed complex boric acid / glycerol, the stabilizing effect of the complex is reduced.

Example 6

In vitro dissolution test

The dissolution rate of the Fluticasone propionate form A nanocrystals of the nanosuspension of the invention was assessed and compared to the dissolution rate of a standard Fluticasone propionate form 1 micronized material (reference sample).

Dissolution profiles of nanocrystals of Fluticasone propionate form A of two nanosuspensions of the invention and of Fluticasone propionate form 1 micronized were performed using a dissolution method.

The particle size of the Fluticasone propionate Form A nanocrystals is 0.434 µm (D50 - median) and the particle size of the Fluticasone propionate form 1 micronized material is 4.64 µm (D50 - median).

The study was performed using a compartment diffusion analysis through a dialysis membrane and sink condition. The sink condition was achieved through the use of a receptor fluid containing 30mM phosphate buffer, pH 7.4 with 5% HPβCD cyclodextrins and also by a complete replacement of the buffer every 24 hours to stay below the saturation

point. The saturation point was estimated to be 5µg/g under those experimental conditions and the measurements performed as well as the buffer replacement have shown a maximum concentration of 1.5µg/g. The study was conducted at a temperature of 37°C. The details of the dissolution test method are provided below:

5 A 5-fold dilution with the formulation vehicle (placebo solution containing all the formulation excipients including the surfactants) of two 0.1% w/w Fluticasone propionate form A nanosuspensions was conducted to obtain a final concentration of 0.02% w/w Fluticasone propionate inside the dialysis device.

 Fluticasone propionate form 1 micronized was suspended in the same phosphate
10 buffer used in the receiving compartment of the dialysis system.

 Fluticasone propionate release was carried at 1-2 RPM.

 Sampling aliquots of 1 mL were withdrawn at pre-determined time intervals (1, 3, 5, 20, 24, 48, 72 hours), and replaced with an equal volume of dissolution medium to maintain a constant total volume of 39 ml in the 50ml tube.

15 These aliquots were immediately centrifuged and the measurements were performed by HPLC

 The results reported in tables 7 - 9 show that the dissolution profiles of the nanocrystals of Fluticasone propionate form A and of the Fluticasone propionate form 1 micronized material were similar despite that the two test samples and the reference sample
20 have different particle size. More specifically, the particle size of Fluticasone propionate Form A nanocrystals is ten-fold smaller ($D_{50} = 0.434 \mu\text{m}$) than the particle size of the micronized Fluticasone propionate form 1 ($D_{50} = 4.64 \mu\text{m}$).

 Since, the solubility of a compound is often intrinsically related to the particle size, as a particle becomes smaller, the surface area to volume ratio increases leading to greater
25 interaction with the solvent which causes an increase in solubility, the results of this study show the unique property of the ophthalmic aqueous fluticasone propionate Form A nanocrystals of the invention, namely on one hand the small particle size (nanoparticles) improves the comfort and the tolerability of the ophthalmic formulation, on the other hand

the slow dissolution rate of the fluticasone propionate active principle allows to avoid a fast and high absorption of fluticasone propionate correlated to the unwanted side-effects associated with the systemic absorption of the steroid.

Table 7: Dissolution test of Fluticasone propionate form A nanocrystals						
Time point (h)	% Dissolution					
	Tube #1	Tube #2	Tube #3	Average %	St. Dev.	RSD
1	0.0%	0.0%	0.0%	0.0%	0.0%	
3	0.2%	1.4%	0.7%	0.8%	0.6%	73.2%
5	1.3%	2.8%	2.4%	2.2%	0.8%	35.6%
19	14.5%	20.4%	18.7%	17.8%	3.0%	16.9%
24	17.5%	24.0%	22.4%	21.3%	3.4%	15.9%
48	38.7%	51.4%	48.6%	46.2%	6.7%	14.4%
72	59.6%	78.1%	74.0%	70.5%	9.7%	13.7%

5

Table 8: Dissolution test of Fluticasone propionate form A nanocrystals						
Time point (h)	% Dissolution					
	Tube #1	Tube #2	Tube #3	Average %	St. Dev.	RSD
1	0.0%	0.0%	0.0%	0.0%	0.0%	
3	0.6%	0.5%	0.8%	0.7%	0.2%	26.7%
5	2.4%	2.0%	2.6%	2.3%	0.3%	11.2%
19	19.0%	18.2%	19.7%	19.0%	0.8%	4.1%
24	22.4%	21.5%	23.2%	22.4%	0.9%	3.8%
48	49.1%	45.6%	50.9%	48.5%	2.7%	5.6%
72	75.1%	69.1%	77.7%	73.9%	4.4%	6.0%

Table 9: Dissolution test of Micronized Fluticasone propionate form 1						
Time point (h)	% Dissolution					
	Tube #1	Tube #2	Tube #3	Average %	St. Dev.	RSD
1	0.0%	0.0%	0.0%	0.0%	0.0%	
3	0.8%	0.5%	0.9%	0.7%	0.2%	31.2%
5	2.9%	1.9%	3.0%	2.6%	0.6%	23.1%
19	20.9%	17.1%	20.3%	19.4%	2.1%	10.7%
24	24.2%	20.2%	23.5%	22.6%	2.2%	9.5%
48	51.1%	44.0%	50.6%	48.6%	4.0%	8.2%
72	77.4%	66.7%	76.2%	73.4%	5.9%	8.0%

Example 7

14-Day repeated dose study of topical ophthalmic aqueous fluticasone

propionate Form A nanocrystals suspensions in Beagle dogs

The purpose of this study was to evaluate the toxicokinetic of fluticasone propionate Form A nanosuspensions of the invention (see Table 10 below) administered via topical application directly to the rim (margin) of upper and lower eyelids of both eyes of Beagle dogs.

Ingredient	% (w/w)	% (w/w)	% (w/w)	% (w/w)
Fluticasone Propionate	0.00	0.005	0.03	0.1
Methylcellulose 4000cP	0.50	0.50	0.50	0.50
Tween 80	0.20	0.20	0.20	0.20
Edetate disodium, dihydrate	0.10	0.10	0.10	0.10
Boric acid	1.00	1.00	1.00	1.00
Sodium chloride	0.055	0.055	0.055	0.055
Glycerol	0.90	0.90	0.90	0.90
Benzalkonium chloride	0.01	0.01	0.01	0.01
Water for Injection	q.s. to 100	q.s. to 100	q.s. to 100	q.s. to 100

Methods

Fifty naïve Beagle dogs (25 males and 25 females), approximately 5-6 months old and weighing 5.7 to 8.8 kg for males and females at the outset of the study were assigned to treatment groups (groups 1-4) and to vehicle group.

Male and female Beagle dogs were dosed with fluticasone propionate at 1.6, 9.6, and 32 µg/day (bilateral QD topical application) or at 64 µg/day (bilateral BID topical application) via eye lid applicator directly to the upper and lower eyelids of both eyes once or twice daily (minimum of 6 hours between doses) for 14 consecutive days.

Blood for toxicokinetic evaluation was collected from all animals at selected time points on Days 1 and 14.

Ophthalmology examinations were performed prior to treatment initiation, during the first and second weeks of dosing and during the last week of recovery. Eyes were scored once daily according to the modified Draize scale.

The reversibility of the effects of Fluticasone Propionate nanosuspension was assessed with a 14-day recovery period.

Results and conclusions

The group mean plasma toxicokinetic parameters are summarized in Table 11 below.

The results show that exposure to fluticasone propionate was dose-dependent increasing with increasing doses. There was no clear evidence of accumulation in male and female animals. There were no discernable gender-related differences in exposure. Systemic exposure (AUC) at the lowest observed adverse effect level associated with corticosteroid-related findings in a 14-day inhalation toxicity study in dogs was 14- and 9-times higher than that observed at the ocular dose of 0.1% QD and BID, in the 14-day topical ocular toxicity study in dogs (Advair-Diskuss-NDA-021077).

There was no evidence of local or systemic toxicity.

Table 11: Plasma Toxicokinetic Parameters of Fluticasone Propionate following topical ocular eyelid margin administration					
Study Day	Ocular Treatment	Dose (µg/day)	Tmax (h)	Cmax (pg/mL)	AUC_{0-24h} (pg.h/mL)
1	0.005% QD	1.6	0.5	32.4±26.4	25.7±18.5
	0.03% QD	9.6	0.5	79.8±70.0	101±102
	0.1% QD	32	0.5	250±219	482±407
	0.1% BID	64	6.5	304±178	914±413
14	0.005% QD	1.6	0.75	28.1±26.6	56.8±65.0
	0.03% QD	9.6	0.5	60.8±48.7	191±335
	0.1% QD	32	0.5	130±155	481±361
	0.1% BID	64	0.5	126±93.6	760±188

Example 8

Evaluation of efficacy and safety of Fluticasone Propionate Form A Nanosuspension for the treatment of acute exacerbations of Blepharitis

The objective of this study was to compare the efficacy and safety of an aqueous ophthalmic formulation of Fluticasone propionate form A nanosuspension of the invention versus placebo in reducing signs and symptoms in subjects with blepharitis.

Test formulation (hereafter FP-Form A-NS)

0.1% w/w fluticasone propionate Form A nanocrystals (mean particle size from 100 nm to 1000 nm) 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10%

w/w edetate disodium dihydrate, 1.0 % w/w boric acid, 0.9% w/w glycerin, 0.01% w/w benzalkonium chloride, 0.055% w/w sodium chloride, hydrochloric acid (1N) and/or sodium hydroxide (1N) as adjusting agents in an amount sufficient for pH from 7.3-7.5, and water q.s. to 100% w/w.

5 **Placebo formulation**

0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid, 0.9% w/w glycerin, 0.01% w/w benzalkonium chloride, 0.055% w/w sodium chloride, hydrochloric acid (1N) and/or sodium hydroxide (1N) as adjusting agents in an amount sufficient for pH from 7.3-7.5, and water q.s. to 100% w/w.

10

Study Design

This was a Phase 2 multi-center, randomized, double-masked, placebo-controlled study evaluating the safety and efficacy of fluticasone propionate Form A nanosuspension 0.1% once a day for the treatment of the signs and symptoms of blepharitis.

15

The target population in this study was adult men and women with a documented history of blepharitis who were experiencing an acute blepharitis exacerbation defined as a minimum score of '1' (on a 4-point scale) for each of Eyelid Margin Redness, Eyelid Debris, and Eyelid Discomfort in both eyes at the Screening and Baseline Visits. A total of 15 subjects were included in the study. Subject ages were between 55 and 80 years old, with an average age of 70.8 years.

20

Fifteen patients have been randomized at three clinical sites across the U.S. Ten patients received FP-Form A-NS and 5 patients received placebo, once a day in the evening for both eyes.

Study visits were as follows: Screening (Day -7 to -3), Baseline/Day 1, Day 4 (\pm 1 day), Day 8 (\pm 1 day), Day 11 (\pm 1 day), Day 14 (- 1 day; last day of treatment), and Day 28/Exit (\pm 2 days; follow up visit).

25

Test nanosuspension (16 μ g of fluticasone propionate per eye) or placebo were applied once a day in the evening. Study drug was self-administered by the subjects.

Evaluation of the efficacy and safety of the Fluticasone Propionate Form A nanosuspension

Efficacy and safety of fluticasone propionate form A nanosuspension (FP-Form A-NS) were compared with placebo at each post-dose visit during the study. In addition of signs and symptoms of blepharitis, this study evaluated signs and symptoms characteristic of dry eye disease, also commonly observed in subjects with blepharitis.

Efficacy

The results of the study reported in Tables 12 and 13 demonstrated that fluticasone propionate form A nanosuspension treatment consistently improved the signs and symptoms in subjects with blepharitis and that subjects treated with fluticasone propionate form A nanosuspension showed a decrease in the composite score of debris, redness and discomfort from baseline and versus subjects treated with placebo.

The results presented in Tables 12 and 13 are related to signs and symptoms of blepharitis in the study eye evaluated after 14 days of treatment and conducted prior to daily eyelid scrub procedures.

The following dry eye symptoms were also evaluated with Visual Analog Scales (VAS) by the subjects: eye dryness, burning-stinging, foreign body sensation, itching, photophobia, pain and blurred vision. The composite VAS score (the average of individual scores of these symptoms) reported in Table 14 demonstrated that fluticasone propionate Form A nanosuspension treatment was efficacious in reducing dry eye symptoms with respect to placebo.

Safety

The treatment with fluticasone propionate Form A nanosuspension of the invention was very well tolerated, all patients completed the treatment. There were no Serious Adverse Events (SAEs) and in particular, no clinically relevant changes in subject's intraocular pressure were observed during treatment or up to two weeks after treatment discontinuation.

The results of this study demonstrate that fluticasone propionate Form A

nanosuspension of the invention is able to reduce both signs and symptoms of blepharitis and dry eye and that the treatment and application method have a safe tolerability profile.

Table 12: Signs and symptoms of blepharitis at Day 14 of treatment with fluticasone propionate form A nanosuspension of the invention (FP-Form A-NS) versus placebo		
Eyelid Margin Redness		
	Placebo	FP-Form A-NS
Baseline (SD)	1.6 (0.89)	1.5 (0.53)
Day 14 (SD)	1.2 (0.45)	0.9 (0.74)
Change from Baseline (SD)	-0.4 (0.55)	-0.6 (0.52)
p values	0.1778	0.0051
FP-Form A-NS vs. Placebo (95% CI)	-0.2 (-0.8, 0.4) p = 0.5000	
Eyelid Debris		
	Placebo	FP-Form A-NS
Baseline (SD)	1.8 (0.45)	1.6 (0.70)
Day 14 (SD)	1.2 (0.45)	0.7 (0.67)
Change from Baseline (SD)	-0.6 (0.55)	-0.9 (0.88)
p value	0.0705	0.0100
FP-Form A-NS vs. Placebo (95% CI)	-0.3 (-1.2, -0.3) p = 0.5000	
Eyelid Discomfort		
	Placebo	FP-Form A-NS
Baseline (SD)	1.8 (0.45)	1.6 (0.52)
Day 14 (SD)	1.4 (1.14)	0.9 (0.88)
Change from Baseline (SD)	-0.4 (0.89)	-0.7 (1.16)
p values	0.3739	0.0886
FP-Form A-NS vs. Placebo (95% CI)	-0.3 (-1.6, 1.0) p = 0.6221	

Table 13: Composite score of Eyelid Margin Redness, Eyelid Debris, and Eyelid Discomfort at 14 Day of treatment with fluticasone propionate form A nanosuspension of the invention (FP-Form A-NS) versus placebo		
Composite Eyelid Debris, Redness & Discomfort	Placebo	FP-Form A-NS
Baseline (SD)	5.2 (1.30)	4.7 (0.82)
Day 14 (SD)	3.8 (1.48)	2.5 (1.90)
Change from Baseline (SD)	-1.4 (0.55)	-2.2 (1.62)
p values	0.0046	0.0020
FP-Form A-NS vs. Placebo (95% CI)	-0.8 (-2.4, 0.8) p = 0.3095	

Table 14: Composite VAS score of dry eye symptoms: eye dryness, burning-stinging, foreign body sensation, itching, photophobia, pain and blurred vision, at 14 Day of treatment with fluticasone propionate form A nanosuspension of the invention (FP-Form A-NS) versus placebo		
Composite VAS score	Placebo	FP-Form A-NS
Baseline (SD)	41.8 (29.72)	44.8 (17.81)
Day 14 (SD)	32.9 (27.17)	26.1 (18.05)
Change from Baseline (SD)	-8.9 (9.37)	-18.8 (19.73)
p values	0.1005	0.0147
FP-Form A-NS vs. Placebo (95% CI)	-9.9 (-30.2, 10.5) p = 0.3142	

Example 9

Evaluation of the stability of the nanosuspension of Example 2

5 The nanosuspension composition prepared in example 2 was subjected to storage stability testing by storing the nanosuspension at three different temperatures and humidity conditions (5°C, 25°C / 40% RH; 40°C / 25% RH) The resuspendability of the nanosuspension, the content of fluticasone propionate, the particle size distribution and the content of benzalkonium chloride were assessed at 1 month and 3-month time-points (see
 10 results reported in Example 3 and Tables 2 and 3), at 5-month time point at 40 °C (Table 15) up to 12 months at 5°C and 25°C (Table 16).

The results reported in tables 15 and 16 show that the nanosuspension was physically and chemically stable upon storage. No change in physical appearance of the nanosuspension upon storage was noticed. The nanosuspension did not show any sign of
 15 chemical degradation as the chemical assay of fluticasone propionate was well within the

limit of 90% - 110% of the label claim upon storage. The related substances and total impurities remained within the specified limits of not more than 4%, upon storage.

Particle size distribution was analyzed using a Horiba LA-950 instrument.

Table 15: 5-month time-point stability data		
Parameter	T0	T = 5-month
	n/a	40°C 25% RH
Fluticasone propionate assay	105.6%	104%
FP Related substances (total)	0.0%	0.11%
Resuspendability	n/a	Resuspends
BAK content	99.1%	103%
PSD results (µm)		
Mean	0.846	0.82
Median	0.425	0.50
Mode	0.362	0.42
D ₁₀	0.202	0.23
D ₉₀	2.219	1.84

5

Table 16: 12-month time-point stability data			
Parameter	T0	T = 12-month	
	n/a	5°C	25°C 40% RH
Fluticasone propionate assay	105.6%	105%	107%
FP Related substances (total)	0.0%	0.61%	0.48%
Resuspendability	n/a	Resuspends	Resuspends
BAK content	99.1%	101%	96%
PSD results (µm)			
Mean	0.846	0.90	0.86
Median	0.425	0.45	0.45
Mode	0.362	0.36	0.36
D ₁₀	0.202	0.21	0.21
D ₉₀	2.219	2.16	2.08

CLAIMS

1. A process for the preparation of sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals having a mean particle size from
5 100 nm to 1000 nm and a concentration of fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:
- a) preparing an aqueous vehicle 1 containing: 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80,
10 hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water to 100% w/w;
 - b) mixing an amount of fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm with an amount of aqueous vehicle 1 to obtain a slurry containing a concentration of fluticasone propionate of 2% w/w;
 - 15 c) applying high-shear, high-speed mixing to the slurry of step b) for at least 10 minutes;
 - d) preparing an aqueous vehicle 2 containing: 1.8% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2%
20 w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w;
 - e) adding an aliquot of the aqueous vehicle 2 to the slurry of step c) to obtain a concentration of fluticasone propionate of about 1% w/w;
 - f) applying high-shear, high-speed mixing to the slurry of step e) till to obtain the
25 targeted mean particle size;
 - g) sterilizing the nanosuspension of step f) by autoclaving;
 - h) preparing an aqueous vehicle 3 containing: 0.9% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium

dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide (1N) to adjust the pH at 7.3 – 7.5 and water to 100% w/w; and sterilizing the aqueous vehicle 3 by filtration;

- 5 i) aseptically adding an aliquot of the sterile aqueous vehicle 3 to the sterilized nanosuspension of step g) to prepare a sterile topical ophthalmic aqueous nanosuspensions containing the targeted concentration of fluticasone propionate nanocrystals Form A;

wherein the nanocrystals of fluticasone propionate Form A have a X-ray powder diffraction
10 pattern of said nanocrystals including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

2. The process according to claim 1 wherein the concentration of fluticasone
15 propionate in the final sterile topical ophthalmic aqueous nanosuspensions is from 0.001% to 0.5% w/w.

3. The process according to claim 1 wherein the concentration of fluticasone propionate in the final sterile topical ophthalmic aqueous nanosuspensions is 0.5% w/w, 0.25% w/w, 0.2% w/w, 0.1% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w.

20 4. The process according to any of claims 1 to 3 wherein the high-shear, high-speed mixing of steps c) and f) is performed at 6000 RPM.

5. The process according to claim 4 wherein in step f) the high-shear, high-speed mixing is applied for at least 10 minutes.

6. The process according to any of claims 1 to 5 wherein the aqueous vehicles 1 and 2
25 are filtered through 0.2 μm filter before their use.

7. The process according to any of claims 1 to 6 wherein the sterilization of step g) is performed by autoclaving the nanosuspension of step f) at about 122 °C for about 40 minutes.

8. A process for the preparation of sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm and a concentration of fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:

- 5 a-1) sterilizing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm;
- b-1) preparing an aqueous vehicle 1 containing: 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80,
10 hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w; and sterilizing said aqueous vehicle 1 by filtration;
- c-1) aseptically mixing an amount of sterilized fluticasone propionate nanocrystals form A with an amount of the sterilized aqueous vehicle 1 to obtain a slurry containing a concentration of fluticasone propionate of 2% w/w;
- 15 d-1) applying high-shear, high-speed mixing to the slurry of step c-1) for at least 10 minutes;
- e-1) preparing an aqueous vehicle 2 containing: 1.8% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2%
20 w/w polysorbate 80, hydrochloric acid 1N / sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water q.s. to 100% w/w; and sterilizing said aqueous vehicle 2 by filtration;
- f-1) aseptically adding an aliquot of the sterilized aqueous vehicle 2 to the slurry of step d-1) to obtain a concentration of fluticasone propionate of about 1% w/w;
- 25 g-1) applying high-shear, high-speed mixing to the slurry of step f-1) till to obtain the targeted mean particle size;
- h-1) preparing an aqueous vehicle 3 containing: 0.9% w/w glycerin, 0.5 % w/w methylcellulose 4000 cp, 1.0% w/w boric acid, 0.1% w/w edetate disodium

dihydrate, 0.055% w/w sodium chloride, 0.01% w/w benzalkonium chloride, 0.2% w/w polysorbate 80, hydrochloric acid 1N and / or sodium hydroxide 1N to adjust the pH at 7.3 – 7.5 and water to 100% w/w; and sterilizing said aqueous vehicle 3 by filtration;

- 5 i-1) aseptically adding an aliquot of the sterilized aqueous vehicle 3 to the nanosuspension of step g-1) to prepare a sterile topical ophthalmic aqueous nanosuspension containing the final concentration of fluticasone propionate nanocrystals Form A;

wherein the nanocrystals of fluticasone propionate Form A have a X-ray powder diffraction
10 pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

9. The process according to claim 8 wherein the concentration of fluticasone
15 propionate in the final sterile topical ophthalmic aqueous nanosuspensions is from 0.001% to 0.5% w/w.

10. The process according to claim 8 wherein the concentration of fluticasone propionate in the final sterile topical ophthalmic aqueous nanosuspensions is 0.5% w/w, 0.25% w/w, 0.2% w/w, 0.1% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w.

20 11. The process according to any of claims 8 to 10 wherein in step a-1) the fluticasone propionate Form A nanocrystals are sterilized by autoclaving a suspension of fluticasone propionate Form A nanocrystals in water for injection having a concentration of fluticasone propionate between 2 % to 20 % w/w.

12. The process according to claim 11 wherein the suspension of fluticasone propionate
25 Form A nanocrystals in water is autoclaved at about 122 °C for about 30 minutes.

13. The process according to any of claims 8 to 12 wherein in step d-1) and step g-1) the high-shear, high-speed mixing is performed at 6000 RPM.

14. The process according to claim 13 wherein in step g-1) the high-shear, high-speed

mixing is applied for at least 10 minutes.

15. The process according to anyone of claims 1 to 14 wherein fluticasone propionate nanocrystals form A are prepared according to the following steps:

- 5 1) preparing a phase I solution comprising 0.45% w/w fluticasone propionate polymorph 1, 23,2% w/w polyethylene glycol 400 (PEG 400), 68.8% w/w polypropylene glycol 400 (PPG 400), 7.6% w/w polysorbate 80 (Tween 80); and filtering the phase I solution through 0.8/0.2 μm Polyethersulfone (PES) filter;
- 10 2) preparing a phase II solution comprising 0.01% w/w benzalkonium chloride, 0.40% (w/w) methyl cellulose 15 cP, 0.1% w/w polyethylene glycol 40 stearate (PEG-40 stearate), citrate buffer to pH 3.4 to 3.8 and water q.s. to 100% w/w; and filtering the phase II solution through 0.8/0.2 μm Polyethersulfone (PES) filter;
- 3) cooling the filtered phase I and phase II solutions to a temperature from 0 to 4°C;
- 15 4) mixing the phase I and the phase II solutions in a reactor equipped with ultrasonic transducer (QSonica Q2000 Ultrasonic transducer) to obtain a phase III suspension of nanocrystals, wherein:
 - the phase I solution and the phase II solution are pumped continuously into the reactor at flow rates of 600 ml/min (phase I solution) and 2400 ml/min (phase II solution) respectively to obtain a phase III suspension;
 - 20 - the volumes ratio phase I and phase II is 1:4;
 - the sonication is applied during the mixing with an output power of 60%;
 - the average temperature of phase III suspension is about 11°C; and
- 5) low shear mixing phase III suspension of step 4) at sufficient speed to create a vortex, at room temperature for a minimum of 30 minutes in absence of sonication;
- 25 6) annealing the phase III suspension at 40°C over a period of time not less than 16 hours;
- 7) preparing a buffer solution comprising 0.2% w/w polyethylene glycol 40 stearate (PEG-40 stearate), 0.2% w/w polysorbate 80 (Tween 80), 0.001% w/w

benzalkonium chloride, 0.05% w/w sodium phosphate monobasic monohydrate, 0.02% w/w sodium phosphate dibasic dihydrate and water q.s. to 100% w/w, having a pH 6.3 ± 0.2 ; and filtering the buffer solution through 0.8/0.2 μm Polyethersulfone (PES) filter;

- 5 8) diluting the phase III suspension of step 6) with the filtered buffer solution wherein the volumes ratio buffer solution and phase III is 1:1;
- 9) centrifuging the diluted phase III suspension to recover the fluticasone propionate nanocrystals Form A and washing the recovered nanocrystals;
- 10) washing the collected nanocrystals with water for injection.

10 16. An ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin consisting of:

(a) 0.001% to 1% w/w fluticasone propionate Form A nanocrystals;

(b) 0.50% w/w methylcellulose 4000 cp;

(c) 0.2% w/w polysorbate 80;

15 (d) 0.10% w/w edetate disodium dihydrate;

(e) 1.0 % w/w boric acid;

(f) 0.9% w/w glycerin;

(g) 0.01% w/w benzalkonium chloride;

(h) 0.055% w/w sodium chloride;

20 (i) hydrochloric acid 1N and/or sodium hydroxide 1N as adjusting agents in an amount sufficient to pH 7.3-7.5; and

(j) water q.s. to 100% w/w,

wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

25

17. The ophthalmic aqueous nanosuspension according to claim 16 wherein the concentration of fluticasone propionate is from 0.001% to 0.5% w/w.

18. The ophthalmic aqueous nanosuspension according to claim 16 wherein the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.2% w/w, 0.1% w/w,
5 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w.

19. The ophthalmic aqueous nanosuspension according to claim 16 wherein the concentration of fluticasone propionate is 0.2% w/w or 0.1% w/w or 0.05% w/w.

20. An ophthalmic aqueous nanosuspension according to anyone of claims 16 to 19 for use in a method of treatment blepharitis, posterior blepharitis, Meibomian gland
10 dysfunction or dry eye disease wherein the method comprises topically applying to eyelids, eyelashes or eyelid margin an effective amount of the ophthalmic aqueous nanosuspension.

21. An ophthalmic aqueous nanosuspension according to anyone of claims 16 to 19 for use in a method of reducing the symptoms and / or clinical signs associated with blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease wherein the method
15 comprises topically applying to eyelids, eyelashes or eyelid margin an effective amount of the ophthalmic aqueous nanosuspension.

22. The ophthalmic aqueous nanosuspension according to claim 16 for use in a method according to claim 20 or 21 wherein the ophthalmic aqueous nanosuspension consists of.

- (a) 0.1% w/w fluticasone propionate Form A nanocrystals;
- 20 (b) 0.50% w/w methylcellulose 4000 cp;
- (c) 0.2% w/w polysorbate 80;
- (d) 0.10% w/w edetate disodium dihydrate;
- (e) 1.0 % w/w boric acid;
- (f) 0.9% w/w glycerin;
- 25 (g) 0.01% w/w benzalkonium chloride;
- (h) 0.055% w/w sodium chloride;
- (i) hydrochloric acid 1N and/or sodium hydroxide 1N as adjusting agents in an amount sufficient to pH 7.3-7.5; and (j) water q.s. to 100% w/w,

wherein said nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2Θ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2Θ , and wherein the nanocrystals are nanoplates having
5 the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.

23. The ophthalmic aqueous nanosuspension for use in a method according to anyone of claims 20 to 22 wherein the method comprises topically applying to eyelids, eyelashes or eyelid margin the ophthalmic aqueous nanosuspension at least once a day for at least two
10 weeks.

Sheet 1/3

Figure 1




Figure 2




Figure 3





Figure 4



INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2020/056832

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K9/14 A61K9/10 A61K47/02 A61K47/10 A61K31/573
 A61P27/00 C07J31/00 C07J71/00
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61K C07J A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 2 847 207 B1 (ACIEX THERAPEUTICS INC [US]) 27 March 2019 (2019-03-27) page 4, paragraph 0009 - page 6, paragraph 0034 page 13, paragraph 0094-0095 page 18, paragraph 0144-0151 page 24, paragraph 0197 examples claims	1-23
A	----- WO 93/21903 A1 (ALCON LAB INC [US]; CHOWHAN MASOOD [US]) 11 November 1993 (1993-11-11) cited in the application page 1, line 5 - page 3, line 10 claims example 1 ----- -/--	1-23

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 30 October 2020	Date of mailing of the international search report 09/11/2020
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer van de Wetering, P

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2020/056832

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2006/229219 A1 (YU ZHI-JIAN [US] ET AL) 12 October 2006 (2006-10-12) page 1, paragraphs 0002, 0009 example 3 -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/IB2020/056832

Patent document cited in search report	Publication date	Patent family member(s)	Publication date			
EP 2847207	B1	27-03-2019	AU 2013259872 A1	27-11-2014		
			BR 112014027681 A2	27-06-2017		
			CA 2872845 A1	14-11-2013		
			CN 104350063 A	11-02-2015		
			CN 107880091 A	06-04-2018		
			DK 3517541 T3	07-09-2020		
			EP 2847207 A1	18-03-2015		
			EP 3517541 A1	31-07-2019		
			EP 3741772 A1	25-11-2020		
			ES 2727474 T3	16-10-2019		
			HK 1207087 A1	22-01-2016		
			HK 1252481 A1	24-05-2019		
			JP 6285419 B2	28-02-2018		
			JP 6564891 B2	21-08-2019		
			JP 6752940 B2	09-09-2020		
			JP 2015520149 A	16-07-2015		
			JP 2018083846 A	31-05-2018		
			JP 2019167382 A	03-10-2019		
			KR 20150013158 A	04-02-2015		
			MX 361886 B	18-12-2018		
			RU 2014149115 A	27-06-2016		
			RU 2018125932 A	12-03-2019		
			US 2018022775 A1	25-01-2018		
			US 2019169224 A1	06-06-2019		
			WO 2013169647 A1	14-11-2013		
			ZA 201408119 B	31-08-2016		
WO 9321903	A1	11-11-1993	AT 300936 T	15-08-2005		
			AU 4233693 A	29-11-1993		
			CA 2132826 A1	11-11-1993		
			DE 69333850 T2	12-01-2006		
			DK 0639070 T3	28-11-2005		
			EP 0639070 A1	22-02-1995		
			ES 2246491 T3	16-02-2006		
			HK 1011615 A1	16-07-1999		
			JP 3337218 B2	21-10-2002		
			JP 3527721 B2	17-05-2004		
			JP H07506377 A	13-07-1995		
			JP 2002177369 A	25-06-2002		
			US 5342620 A	30-08-1994		
			WO 9321903 A1	11-11-1993		
			US 2006229219	A1	12-10-2006	AU 2006235114 A1
BR PI0608645 A2	19-01-2010					
CA 2604813 A1	19-10-2006					
CN 101155605 A	02-04-2008					
EP 1871432 A2	02-01-2008					
JP 2008538823 A	06-11-2008					
US 2006229219 A1	12-10-2006					
WO 2006110482 A2	19-10-2006					